Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Tuesday, March 26, 2013
Hyperpigmentation common adverse event of interferon-based chronic HCV therapy
Researchers evaluated 77 patients with chronic hepatitis C treated with pegylated interferon alfa-2b and ribavirin at the University Hospital of Nice in France. All had received therapy for 3 months or longer. Dermoscopic and clinical examinations were performed on the skin, nails and mucous membranes of each participant, along with skin biopsies if necessary.